Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
BMC Pregnancy Childbirth ; 21(1): 317, 2021 Apr 21.
Artículo en Inglés | MEDLINE | ID: mdl-33882864

RESUMEN

BACKGROUND: Obstetric haemorrhage is the leading cause of maternal death worldwide, 99% of which occur in low and middle income countries. The majority of deaths and adverse events are associated with delays in identifying compromise and escalating care. Management of severely compromised pregnant women may require transfer to tertiary centres for specialised treatment, therefore early recognition is vital for efficient management. The CRADLE vital signs alert device accurately measures blood pressure and heart rate, calculates the shock index (heart rate divided by systolic blood pressure) and alerts the user to compromise through a traffic light system reflecting previously validated shock index thresholds. METHODS: This is a planned secondary analysis of data from the CRADLE-3 trial from ten clusters across Africa, India and Haiti where the device and training package were randomly introduced. Referral data were prospectively collected for a 4-week period before, and a 4-week period 3 months after implementation. Referrals from primary or secondary care facilities to higher level care for any cause were recorded. The denominator was the number of women seen for maternity care in these facilities. RESULTS: Between April 1 2016 and Nov 30th, 2017 536,223 women attended maternity care facilities. Overall, 3.7% (n = 2784/74,828) of women seen in peripheral maternity facilities were referred to higher level care in the control period compared to 4.4% (n = 3212/73,371) in the intervention period (OR 0.89; 0.39-2.05) (data for nine sites that were able to collect denominator). Of these 0.29% (n = 212) pre-intervention and 0.16% (n = 120) post-intervention were referred to higher-level facilities for maternal haemorrhage. Although overall referrals did not significantly reduce there was a significant reduction in referrals for obstetric haemorrhage (OR 0.56 (0.39-0.65) following introduction of the device with homogeneity (i-squared 26.1) between sites. There was no increase in any bleeding-related morbidity (maternal death or emergency hysterectomy). CONCLUSIONS: Referrals for obstetric haemorrhage reduced following implementation of the CRADLE Vital Signs Alert Device, occurring without an increase in maternal death or emergency hysterectomy. This demonstrates the potential benefit of shock index in management pathways for obstetric haemorrhage and targeting limited resources in low- middle- income settings. TRIAL REGISTRATION: This study is registered with the ISRCTN registry, number ISRCTN41244132 (02/02/2016).


Asunto(s)
Vías Clínicas/organización & administración , Servicios de Salud Materna , Sistemas de Entrada de Órdenes Médicas/estadística & datos numéricos , Hemorragia Posparto , Derivación y Consulta/estadística & datos numéricos , Adulto , Países en Desarrollo , Diagnóstico Precoz , Femenino , Humanos , Servicios de Salud Materna/normas , Servicios de Salud Materna/estadística & datos numéricos , Mortalidad Materna , Evaluación de Procesos y Resultados en Atención de Salud , Hemorragia Posparto/diagnóstico , Hemorragia Posparto/mortalidad , Hemorragia Posparto/prevención & control , Embarazo , Tiempo de Tratamiento/normas , Tiempo de Tratamiento/estadística & datos numéricos , Signos Vitales
2.
BMC Pregnancy Childbirth ; 20(1): 698, 2020 Nov 16.
Artículo en Inglés | MEDLINE | ID: mdl-33198663

RESUMEN

BACKGROUND: Full dilatation caesarean sections are associated with recurrent early spontaneous preterm birth and late miscarriage. The risk following first stage caesarean sections, are less well defined, but appears to be increased in late-first stage of labour. The mechanism for this increased risk of late miscarriage and early spontaneous preterm birth in these women is unknown and there are uncertainties with regards to clinical management. Current predictive models of preterm birth (based on transvaginal ultrasound and quantitative fetal fibronectin) have not been validated in these women and it is unknown whether the threshold to define a short cervix (≤25 mm) is reliable in predicting the risk of preterm birth. In addition the efficacy of standard treatments or whether benefit may be derived from prophylactic interventions such as a cervical cerclage is unknown. METHODS: There are three distinct components to the CRAFT project (CRAFT-OBS, CRAFT-RCT and CRAFT-IMG). CRAFT-OBS: Observational Study; To evaluate subsequent pregnancy risk of preterm birth in women with a prior caesarean section in established labour. This prospective study of cervical length and quantitative fetal fibronectin data will establish a predictive model of preterm birth. CRAFT-RCT: Randomised controlled trial arm; To assess treatment for short cervix in women at high risk of preterm birth following a fully dilated caesarean section. CRAFT-IMG: Imaging sub-study; To evaluate the use of MRI and transvaginal ultrasound imaging of micro and macrostructural cervical features which may predispose to preterm birth in women with a previous fully dilated caesarean section, such as scar position and niche. DISCUSSION: The CRAFT project will quantify the risk of preterm birth or late miscarriage in women with previous in-labour caesarean section, define the best management and shed light on pathological mechanisms so as to improve the care we offer to women and their babies. TRIAL REGISTRATION: CRAFT was prospectively registered on 25th November 2019 with the ISRCTN registry ( https://doi.org/10.1186/ISRCTN15068651 ).


Asunto(s)
Aborto Espontáneo/epidemiología , Cerclaje Cervical/métodos , Cesárea/estadística & datos numéricos , Nacimiento Prematuro/prevención & control , Dilatación , Femenino , Humanos , Primer Periodo del Trabajo de Parto , Trabajo de Parto , Estudios Multicéntricos como Asunto , Estudios Observacionales como Asunto , Embarazo , Nacimiento Prematuro/epidemiología , Estudios Prospectivos , Ensayos Clínicos Controlados Aleatorios como Asunto
3.
Pregnancy Hypertens ; 21: 35-37, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32388118

RESUMEN

We aimed to establish a rule-in threshold for the DELFIA Xpress placental growth factor (PlGF) 1-2-3 test. Plasma EDTA samples from 305 women presenting with suspected pre-eclampsia before 35 weeks' gestation were analysed using three different PlGF-based tests: PlGF 1-2-3 test (Perkin Elmer); Triage PlGF test (Quidel); Elecsys immunoassay sFlt-1/PlGF ratio (Roche). The rule-in threshold for PlGF 1-2-3 test created with equivalent specificity of the Quidel and Roche tests was 50 pg/ml. This can be used as a rule-in test for diagnosis of preterm pre-eclampsiarequiring delivery within 14 days (specificity 95.0% (95% CI 91.7-97.2%), positive predictive value50 (95% CI 30.6-69.4%), positive likelihood ratio 10.7 (5.8-20).


Asunto(s)
Factor de Crecimiento Placentario/sangre , Preeclampsia/diagnóstico , Biomarcadores/sangre , Femenino , Edad Gestacional , Humanos , Inmunoensayo , Valor Predictivo de las Pruebas , Embarazo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA